CI leaders must balance diverse responsibilities to ensure insights support strategic decisions and drive informed actions across the organisation.| Evaluate
Real-time tracking, analysis, and strategic intelligence to support decision-making processes across drug development, manufacturing, and market competition.| Evaluate
Meet Evaluate in Munich at Pharma CI Europe and find out how our CI services help you achieve your strategic goals.| Evaluate
Download the GLP-1 Obesity Deal Trends Report for analysis on dealmaking, investment, and innovation in the obesity therapeutics market. Essential for pharma, biotech, and financial professionals in business development, licensing, and portfolio strategy.| Evaluate
Recently, I was delighted to attend the Pharma CI event in Newark, NJ which brought together competitive intelligence (CI) leaders from across the pharmaceutical industry to tackle the key challenges that face CI teams every day. In addition to catching up with familiar faces and meeting new people, I had the pleasure of taking the […]| Evaluate
Trusted commercial intelligence, consensus forecasts, news and analysis for pharma, biotech and medtech industry - Explore Evaluate| Evaluate
Leverage biotechs for pipeline boost with reduced risk. Navigate the large ecosystem to select assets fitting your strategy for successful partnerships.| Evaluate
Andrew Ward discusses the role of analogs in pharmaceutical forecasting and shares best practices their successful use in this short video.| Evaluate
Discover how pharma and biotech are converging in a consumer-driven landscape. Learn about direct-to-patient models, carve-out deals, and why some biotechs are going solo. Get early access to insights from “Pharma v Biotech: New Rules?” and stay ahead of the curve.| Evaluate
Discover how biotech and Big Pharma are evolving under pressure. From China’s R&D surge to pricing reform, we reveal key market shifts that are reshaping the pharma landscape.| Evaluate
Learn how to improve pharmaceutical sales forecasting accuracy. Discover methods, data sources, and eventing techniques to create reliable sales forecasts in pharma.| Evaluate
Discover how a configurable treatment value model empowers pharmaceutical companies, healthcare professionals, and patients in emerging therapeutic markets—enhancing drug launch strategies, treatment access, and clinical decision-making with real-world data and cost transparency.| Evaluate
All-in-one pharmaceutical forecasting platform. FC365 simplifies complex forecasting via a centralised, shared cloud-based interface.| Evaluate
Pharma forecasting training, providing insight into sales, oncology and epi-based techniques, delivered by leading experts in the industry.| Evaluate
With Evaluate Data Feeds, integrate forecast, trial and key event data into your systems and workflows, saving time and accelerating strategic decision making| Evaluate
Evaluate's pharmaceutical consulting and analytics team provide expert solutions for your unique scientific, clinical, and commercial challenges, enhancing your strategy.| Evaluate
Biomedtracker provides a holistic view of the drug development landscape with real-time tracking of events, catalysts and deals.| Evaluate
Find out how Evaluate can help you - pharma & biotech, financial services, management consultancies, medtech & service providers to the pharma industry| Evaluate
Andrew Ward discusses the continued relevance of Excel-based forecasting as part of a forecasters software toolkit, highlighting its flexibility, transparency, and universal accessibility.| Evaluate
The obesity sector has witnessed robust GLP-1 deal making with pharma companies showing unprecedented appetite for strategic pharma deals.| Evaluate
Read how a biotech VC firm sharpened investment strategy with data-driven insights, rare disease focus, and lifecycle support| Evaluate
Discover how pharma forecasting teams can navigate Loss of Exclusivity (LoE) with precision. Learn strategies to manage asset saturation, biosimilar impact, and regional planning in today’s competitive pipeline landscape.| Evaluate
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q2 2025.| Evaluate
Explore Evaluate’s Q2 2025 biopharma report for the latest insights on M&A, IPOs, venture funding, and China’s rising influence. Essential reading for pharma, biotech, and pharma investors.| Evaluate
BIO International 2025 highlights, including trends in biotech investment, M&A activity, licensing, and the role of China in global biopharma. Download now for expert commentary, market statistics, and strategic guidance.| Evaluate
“Nuclear winter” and “extinction event” were two of the less-than-positive terms used during last month’s BIO International convention to describe the biotech investment landscape..| Evaluate
Pharma industry trends 2025. Find 3 standout insights from Evaluate’s World Preview 2025 webinar, including the rise of integrated biotechs & China’s growing role. Watch now on demand.| Evaluate
Discover key insights from Evaluate’s World Preview 2025 infographic, including GLP-1 growth, China’s biotech ascent, and looming patent expiries. Download now.| Evaluate
Master your pharma forecasting with epidemiology, patient-flow, and sales-based methodologies. Download the eBook for expert insights and best practices.| Evaluate
Discover how a clinical-stage biotech partnered with J+D Forecasting to transform its oncology forecasting—accelerating Phase III launch readiness, building internal capability, and enabling strategic pipeline decisions with Onco+.| Evaluate
This one-page guide highlights five expert tips tohelp you navigate the unique challenges of oncology forecasting withgreater confidence.| Evaluate
Pharma market growth forecasts and drug sales to 2030 reflect solid underlying demand. But much is changing across the biopharma landscape.| Evaluate
Drug sales to hit $1.75T by 2030, led by GLP-1s and China’s biotech rise amid global pharma shifts.| Evaluate
Key announcements and data from the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), with accompanying analyses.| Evaluate
Key considerations for creating more accurate patient-based product forecasts.| Evaluate
Evaluate’s custom analytics team help you to address unique commercial challenges. We answer key asset, portfolio, and corporate strategy-related questions, powered by the combined resources of Norstella.| Evaluate
Biotech industry insights. Discover the key factors for biotech commercialization success, including strategic planning, hiring, and funding.| Evaluate
Choosing the best time series algorithm for accurate pharmaceutical sales forecasts. Explore automated and manual approaches.| Evaluate
Discover 3 key insights from our webinar on first to market advantage in the pharma industry. Learn how these findings can impact your portfolio strategy.| Evaluate
Discover the top 15 market catalysts in Q2 2025 across drugs, devices, diagnostics, and deals.| Evaluate
Biotechs sponsor a growing share of new drugs & many are commercializing their products too. What are the steps to successful biotech commercialization?| Evaluate
Insmed CEO Will Lewis talked to Evaluate about the biotech’s orphan drug strategy, why it is still committed to rare diseases, and how orphan drug benefits might be better targeted.| Evaluate
What did 2024’s biggest biopharma deals reveal about the state of the industry? Find out more in our Deal-making Roundup.| Evaluate
In this session we’ll dive deeper into addressing pain points and equipping attendees with practical solutions like standardized forecasting, automation, and cloud-based tools.| Evaluate
The landscape for competitive intelligence means trying to support a lot of different needs. It’s hardly surprising that CI teams can feel pulled in many directions.| Evaluate
The lines between orphan drugs and mainstream prescription drugs are blurring. In this infographic, we look at the top orphan drugs and the wider market for drugs for rare diseases.| Evaluate
Orphan drugs for rare diseases are set to make up one fifth of the of all prescription drug sales by 2030. This report investigates the orphan drug landscape out to 2030.| Evaluate
Biotech FDA approvals accounted for two thirds of the 2024 total – a big shift from 2023. We investigate the drivers and challenges for small players going it alone.| Evaluate
2024 Review of Pharma - Analysis of the state of dealmaking, investment & stock price performance of the biopharma sector in 2024| Evaluate
Join us for an insightful session, as we tackle the common challenges associated throughout the Long-Range Planning cycle.| Evaluate
Discover our comprehensive thought leadership library featuring the latest data-driven reports, captivating infographics, and insightful articles addressing key industry issues, niche topics, and everything in between.| Evaluate
What does 2025 have in store for pharma forecasting teams? We explore the evolving role of forecasting teams in the pharmaceutical industry.| Evaluate
How can forecasters use analogue forecasting to accurately predict a new drug’s impact on the treatment landscape?| Evaluate
Explore our infographic on forecasting in pharmaceutical product management, highlighting key stakeholder considerations throughout the product lifecycle.| Evaluate
.Prepare for the patent cliff's impact on sales. This expert report from J+D Forecasting explores market shifts and forecasting strategies.| Evaluate
The oldest hub-and-spokes pharma companies are over 10 years old – has the portfolio biotech model been validated?| Evaluate
The term CDMO has become ubiquitous in the pharmaceutical industry over the past decade but does it represents a paradigm change in how drugs are developed and manufactured?| Evaluate
Evaluate’s latest report features 2025 pharma forecasts for top-selling drugs, biggest companies and potential novel drug approvals for the year ahead.| Evaluate
Your at-a-glance snapshot of Evaluate’s 2025 pharma forecasts of top drugs, companies and potential drug launches.| Evaluate
Pharma shifts to predictable trends, focusing on major drugs for big diseases. Evaluate’s 2030 forecast explores obesity and new tech.| Evaluate
Pharma M&A and IPOs started strong in 2024 but saw significant drops in Q2, with fewer deals and only three companies going public.| Evaluate
Discover key strategies for forecasting rare diseases, affecting 300M+ people globally. Learn from case studies and epidemiological models in our guide.| Evaluate
Explore Evaluate's analysis of 200 top-selling drugs to uncover what makes billion-dollar blockbusters. Get the Billion Dollar Blueprint infographic now.| Evaluate
Find out how Evaluate can help you - pharma & biotech, financial services, management consultancies, medtech & service providers to the pharma industry.| Evaluate
Access all the crucial insights you need with Competitive Landscape Analysis, facilitating risk assessment, uncovering unmet needs, and gaining deeper insights into your growth drivers and product differentiators. Empower your SEO strategy with these optimized descriptions.| Evaluate
Company Profiling helps you discover, profile, and track the ideal companies aligned with your growth strategy.| Evaluate
Evaluate Commercial Opportunity Assessment integrates company financials, product attributes, consensus forecasts, and market insights to guide your strategic product placement effectively.| Evaluate
Unlock accurate, unbiased, and timely insights into pharmaceutical asset potential through our solutions. Forecast product-level risks, costs, and timelines to empower confident commercial decision-making.| Evaluate
If you missed our dealmaking trends webinar, here are 3 things we learned about unpartnered assets, M&A and partnerships.| Evaluate
Utilize Evaluate for Market Opportunity Sizing to gain comprehensive insights into the potential clinical and commercial differentiation of new assets, their competitive landscape, and the market dynamics.| Evaluate
Discover how the loss of exclusivity for biologics by 2030 opens $120B in opportunities for biosimilars, shaping the industry's future.| Evaluate
Biopharma faces ongoing challenges in 2024, yet Q3 IPOs and venture funding show promise. M&A remains low. Dive into our latest analysis.| Evaluate
Pharmacological intervention can shift excess body weight, but questions remain. Explore market size, pipeline value, and key insights.| Evaluate
MASH UP? Are we witnessing the next multi-billion dollar breakthrough in liver health? Explore the possibilities in our latest eBook.| Evaluate
Product Lifecycle Forecasting: This informative playbook covers everything you need to know about how forecasting demands and considerations evolve at each stage of a product's journey.| Evaluate
Explore how pharmaceutical companies add blockbuster drugs. Learn about internal development vs. acquisitions, strategic timing, top companies, and acquisition benefits.| Evaluate
Kelly's an expert in supporting competitive intelligence workflows & ensuring CI teams maximise the value of market intelligence for stakeholders.| Evaluate
Pharma companies must balance R&D and acquisitions. Evaluate Pharma's analysis of the top 15 firms by 2023 sales reveals spending trends.| Evaluate
Effective forecasting stands as a cornerstone for pharmaceutical and biotechnology enterprises, shaping strategies, mitigating risks, and propelling innovation forward. Elevate your decision-making with Evaluate Pharma, the premier destination for consensus forecasts trusted by pharmaceutical firms, investment banks, and consultancies alike.| Evaluate
Leverage Evaluate's benchmarking and negotiation tools to gain insights into the dealmaking landscape, supported by extensive historical data for context.| Evaluate
Back from BIO: The Evolving Biotech Investment Landscape| Evaluate
All parts of the pharma ecosystem are touched by speculation about AI. From drug discovery to clinical trials.| Evaluate
Missed our World Preview webinar? Check it out on-demand to get the highlights from our panel as they discuss the latest pharma forecasts.| Evaluate
Forecasting serves to help pharmaceutical companies identify market opportunities and risks, particularly when taking a sales-based approach.| Evaluate
Good pharmaceutical forecasting requires robust processes to comply with best practices and create accurate results. Find out what the processes are.| Evaluate
Over the last 10 years, large pharma companies have spent an average of $120bn across pharma R&D and business development investments.| Evaluate
Our World Preview report features pharma forecasts out to 2030. The theme this year is “Pharma’s Growth Boost”.| Evaluate
Missed our webinar on orphan drugs? Catch up on the discussion with experts Melanie Senior, Puru Gaur, and Stephanie Léouzon on demand.| Evaluate
Empower your pharmaceutical forecasting with FC365. Streamline processes, save time, and enhance efficiency with our pharma-specific SaaS platform.| Evaluate
Neurology is experiencing a revival with notable clinical advancements and increased deal activity from pharmaceutical giants.| Evaluate
Obesity drugs will dominate 2030 forecasts, with new technologies and strong pharma acquisitions boosting biotech growth.| Evaluate